First, PD-L1 expression is dynamic and its expression in tumor samples before, during, or after previous treatment or immunotherapy could have affected PD-L1 immunohistochemistry (IHC) results [25] Second, each study used a different anti-PD-L1 IHC detection assay developed by different companies [26, 27]. The gene discussed is CD274; the disease is neoplasm.